Carleton M. Sherman

Efflux‐Pump–Derived Multiple Drug Resistance to Ethambutol Monotherapy in<i>Mycobacterium tuberculosis</i>and the Pharmacokinetics and Pharmacodynamics of Ethambutol

Shashikant Srivastava, Sandirai Musuka, Carleton M. Sherman et al. · The Journal of Infectious Diseases · 2010 · 128 citations · Full text

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis

Shashikant Srivastava, Gesham Magombedze, Thearith Koeuth et al. · Antimicrobial Agents and Chemotherapy · 2017 · 110 citations · Full text

Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model

Beatriz E. Ferro, Shashikant Srivastava, Devyani Deshpande et al. · Antimicrobial Agents and Chemotherapy · 2015 · 58 citations · Full text

Antibiotic Adjuvant, Antimicrobial Chemotherapy, Physiologically-based Pharmacokinetic Modeling +20

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling

Shashikant Srivastava, Carleton M. Sherman, Claudia Meek et al. · Antimicrobial Agents and Chemotherapy · 2011 · 46 citations · Full text

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

Shashikant Srivastava, Jotam G. Pasipanodya, Geetha Ramachandran et al. · EBioMedicine · 2016 · 45 citations · Full text